Small molecule · Inhibitor of X-linked inhibitor of apoptosis protein (XIAP) and CASP8 and FADD-like apoptosis regulator (CFLAR) · developed by Kazia Therapeutics
Idronoxil is a synthetic flavonoid derivative that activates the mitochondrial caspase system, inhibits XIAP, and disrupts FLIP expression, promoting tumor cell apoptosis. It also stabilizes the cleavable complex of DNA topoisomerase II. It has been studied in unspecified adult solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00022295 | Phase 1 | Unspecified Adult Solid Tumor, Protocol Specific | Completed | KZIA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Unspecified Adult Solid Tumor, Protocol Specific
See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KZIA catalysts and pipeline →